|
|
| HUMAN GENOME SCIENCES ANNOUNCES LICENSE AGREEMENT WITH PFIZER | |
|
ROCKVILLE, Maryland -- December 18, 2003 -- Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today a license agreement with Pfizer, Inc. (NYSE: PFE) under which Pfizer has acquired non-exclusive worldwide rights to research, develop and commercialize products based on gene sequences from Staphylococcus aureus, for potential human and animal use. The agreement announced today amends a 1996 agreement with Pharmacia & Upjohn, Inc., which was acquired by Pfizer in early 2003.1 Human Genome Sciences will receive from Pfizer a one-time license fee of an undisclosed amount under the terms of the amended agreement, and Pfizer is relieved of any other obligation under the prior agreement. For additional information on Human Genome Sciences, please visit our web site at www.hgsi.com. Health professionals interested in clinical studies involving HGSI products are encouraged to inquire via the Contact Us section of the Human Genome Sciences web site, www.hgsi.com/products/request.html, or by calling us at (301) 610-5790, extension 3550. Human Genome Sciences is a company with the mission to treat and cure disease by bringing new gene-based drugs to patients. HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. # # # Footnote: 1. (HGSI Press Release) Human Genome Sciences And Pharmacia & Upjohn Collaborate To Develop Antimicrobial Agents. October 9, 1996.
CONTACT: |